MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline

ROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced the signing of a Strategic Platform License Agreement (SPL) with Anocca AB, a leading, clinical stage T-cell immunotherapy company. Anocca AB will deploy MaxCyte’s Flow Electroporation^® technology and ExPERT™ platform to support the scalable development and manufacturing of its deep pipeline of T-cell receptor engineered T-cell (TCR-T) cell therapies.

Read more at globenewswire.com